Generalized, pruritic, ulcerating maculopapular rash necessitating cessation of sirolimus in a liver transplantation patient

Liver Transplantation

Volumn 11, Issue 8, 2005, Pages 987-989

  Tracey, Christopher ^a,b   Hawley, Carmel ^a   Griffin, Anthony Donald ^a   Strutton, Geoff ^a   Lynch, Stephen ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b MATER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PREDNISONE; RAPAMYCIN; TRIAMCINOLONE ACETONIDE;

ADULT; ALOPECIA; ARTICLE; CASE REPORT; DRUG ERUPTION; DRUG USE; DRUG WITHDRAWAL; FEMALE; GRAFT FAILURE; GRAFT REJECTION; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NEUTROPENIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PRURITUS; REFRACTORY ANEMIA; REOPERATION; SKIN BIOPSY;

DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MIDDLE AGED; PRURITUS; SIROLIMUS; SKIN ULCER;

EID: 23744450635     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20499     Document Type: Article

References (16)

1. Watson CJ, Friend PJ, Jamieson NV, Frick TW, Alexander G, Gimson AE, Calne R. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 1999;67:505-509.
2. Vasquez EM. Sirolimus: a new agent for prevention of renal allograft rejection. Am J Health Syst Pharm 2000;57:437-448.
3. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975;28:727-732.
4. Reynolds NJ, Al Daraji WI. Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin Exp Dermatol 2002;27:555-561.
5. Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 2000;69:2085-2090.
6. Morelon E, Stern M, Israel-Biet D, Correas JM, Danel C, Mamzer-Bruneel MF, Kreis H. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001;72:787-790.
7. Wilczek HE, Brattstrom C. Sirolimus experience at a Swedish transplantation center. Transplant Proc 2003;35:84s-88s.
8. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001;71:271-280.
9. Neff GW, Montalbano M, Tzakis AG. Ten years of sirolimus therapy in orthotopic liver transplant recipients. Transplant Proc 2003;35:209s-216s.
10. Machado PG, Felipe CR, Hanzawa NM, Park SI, Garcia R, Alfieri F, et al. An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination. Clin Transplant 2004;18:28-38.
11. Paul LC. Overview of side effects of immunosuppressive therapy. Transplant Proc 2001;33:2089-2091.
12. Groetzner J, Kaczmarek I, Landwehr P, Mueller M, Daebritz S, Lamm P, et al. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients. Eur J Cardiothorac Surg 2004;25:333-341.
13. Kniepeiss D, Iberer F, Grasser B, Schaffellner S, Tscheliessnigg KH. Sirolimus and mycophenolate mofetil after liver transplantation. Transpl Int 2003;16:504-509.
14. Schaffellner S, Jakoby E, Kniepeiss D, Stadlbauer V, Daller D, Iberer F, Tscheliessnigg KH. Center experience in liver transplantation (LTX): management of dermal side effects caused by sirolimus. Int Immunopharmacol 2005;5:137-140.
15. Hardinger KL, Cornelius LA, Trulock EP 3rd, Brennan DC. Sirolimus-induced leukocytoclastic vasculitis. Transplantation 2002;74:739-743.
16. Kaplan MJ, Ellis CN, Bata Csorgo Z, Kaplan RS, Endres JL, Fox DA. Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes. Arch Dermatol 1999;135:553-557.